Drugs Made In America Acquisition Corp. Rights (DMAAR) financials · $1.8M cap
Lician Pro · $19.99/mo or $149/yrCompare AAPL vs MSFT
Drugs Made In America Acquisition Corp. Rights (DMAAR) $1.8M cap.
| Line | FY2025 | FY2024 |
|---|---|---|
| Operating Income | -$2.82M | -$279.8K |
| Net Income | $5.94M | -$279.8K |
| EPS (Diluted) | N/A | N/A |
| Line | FY2025 | FY2024 |
|---|---|---|
| Total Assets | $239.9M | $550.8K |
| Current Assets | $12.2K | $4.99K |
| Cash & Equivalents | $6.14K | $1.35K |
| Total Liabilities | $7.28M | $795.7K |
| Current Liabilities | $376.2K | $795.7K |
| Shareholders' Equity | -$7.26M | -$244.8K |
| Retained Earnings | -$7.27M | -$279.8K |
| Line | FY2025 | FY2024 |
|---|---|---|
| Operating Cash Flow | -$539.2K | -$172.3K |
| Investing Cash Flow | -$231.2M | N/A |
| Financing Cash Flow | $231.7M | $173.6K |
FAQ
What is DMAAR P/E and revenue?
Drugs Made In America Acquisition Corp. Rights (DMAAR) $1.8M cap.
What is DMAAR revenue?
DMAAR income-statement cache has no revenue figure yet.
Is DMAAR profitable?
Drugs Made In America Acquisition Corp. Rights last cached net income is $5.94M (FY2025).
What are DMAAR total assets?
Drugs Made In America Acquisition Corp. Rights last cached total assets are $239.9M (FY2025).
What is DMAAR free cash flow?
No cached cash-flow row for DMAAR yet.
Not investment advice. Cached statements, not a live tape.